3D Medicines (HKSE:01244) Change In Receivables : HK$79.5 Mil (TTM As of Dec. 2023)

View and export this data going back to 2022. Start your Free Trial

What is 3D Medicines Change In Receivables?

3D Medicines's change in receivables for the quarter that ended in Dec. 2023 was HK$139.6 Mil. It means 3D Medicines's Accounts Receivable declined by HK$139.6 Mil from Jun. 2023 to Dec. 2023 .

3D Medicines's change in receivables for the fiscal year that ended in Dec. 2023 was HK$79.5 Mil. It means 3D Medicines's Accounts Receivable declined by HK$79.5 Mil from Dec. 2022 to Dec. 2023 .

3D Medicines's Accounts Receivable for the quarter that ended in Dec. 2023 was HK$6.0 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. 3D Medicines's Days Sales Outstanding for the six months ended in Dec. 2023 was 3.53.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. 3D Medicines's liquidation value for the six months ended in Dec. 2023 was HK$486.5 Mil.

3D Medicines Change In Receivables Historical Data

The historical data trend for 3D Medicines's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

3D Medicines Change In Receivables Chart

3D Medicines Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Change In Receivables

-0.35

-79.30

-14.59

79.52

3D Medicines Semi-Annual Data
	Dec20	Dec21	Jun22	Dec22	Jun23	Dec23
Change In Receivables	Get a 7-Day Free Trial			-	-51.22	34.21	-60.06	139.58

3D Medicines Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$79.5 Mil.

3D Medicines (HKSE:01244) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

3D Medicines's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	5.971	/	308.879	*	91
=	3.53

2. In Ben Graham's calculation of liquidation value, 3D Medicines's accounts receivable are only considered to be worth 75% of book value:

3D Medicines's liquidation value for the quarter that ended in Dec. 2023 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	1090.035	-	610.544	+	0.75 * 5.971	+	0.5 * 5.045
=	486.5

3D Medicines Change In Receivables Related Terms

Thank you for viewing the detailed overview of 3D Medicines's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

3D Medicines (HKSE:01244) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » 3D Medicines Inc (HKSE:01244) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 3 and No. 5, Laiyang Road, Shandong, Qingdao, CHN

Website

https://www.3d-medicines.com

3D Medicines Inc is a commercial-stage biopharmaceutical company that researches, develops, and commercialization of drugs in the field of managing cancer as a chronic disease. It develops differentiated immuno-oncology drugs, helping cancer patients live with prolonged survival time and quality of life.

Executives

Gong Zhaolong	2101 Beneficial owner
Zhu Pai	2101 Beneficial owner
Dragon Prosper Holdings Limited	2101 Beneficial owner
Simcere Pharmaceutical Group Limited	2101 Beneficial owner
Gong Zhaolong	2501 Other
Immunal Medixin Us Limited	2101 Beneficial owner
Kastle Limited
Shanghai Zhenlu Enterprise Management Consulting Partnership (limited Partnership)	2101 Beneficial owner
Shenzhen Efung Holding Co., Ltd.	2201 Interest of corporation controlled by you
Shenzhen Efung Investment Management Enterprise (l.p.)	2201 Interest of corporation controlled by you
Shenzhen Efung Ruishi Investment Enterprise (limited Partnership)	2201 Interest of corporation controlled by you
Zhu Jinqiao	2103 Interests held jointly with another person

3D Medicines (HKSE:01244) Headlines

No Headlines